Mounjaro vs Ozempic: Which One Destroys More Muscle? (New Research)

Two of the most prescribed weight loss drugs in the world – Ozempic (semaglutide) and Mounjaro (tirzepatide) – are now being scrutinised for a side effect that doctors rarely mention in the consultation room: significant muscle loss. A growing body of research shows that while both drugs deliver impressive fat reduction, they may also strip away lean muscle at a rate that concerns sports medicine physicians and metabolic health specialists alike. Understanding which drug is worse for your muscle mass, and what you can do about it, could determine your long-term health outcomes far beyond the number on the scale.

The Muscle Loss Problem With GLP-1 Drugs

GLP-1 receptor agonists work by mimicking a gut hormone that slows gastric emptying, reduces appetite, and triggers feelings of fullness. They are extraordinarily effective at reducing total body weight – but weight loss is not the same as fat loss. In clinical trials, roughly 25 to 40 percent of the weight lost on semaglutide and tirzepatide has been lean mass, including skeletal muscle.

To put this in perspective: a patient who loses 20 kg on Ozempic over 18 months may lose 5 to 8 kg of that as muscle. Muscle is metabolically active tissue. Losing it lowers your resting metabolic rate, making weight maintenance harder after stopping the drug. It also reduces physical strength, increases fall risk in older adults, and impairs insulin sensitivity – the very condition these drugs are often prescribed to treat.

This has led researchers to ask a critical question: does it matter which drug you take? Is Mounjaro better or worse than Ozempic for muscle preservation?

How Ozempic and Mounjaro Work Differently

Ozempic contains semaglutide, a GLP-1 receptor agonist. It activates one hormone receptor pathway – the glucagon-like peptide-1 receptor – which primarily affects appetite and blood glucose.

Mounjaro contains tirzepatide, a dual agonist that activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP receptors are found not just in the gut but also in fat tissue and, importantly, in skeletal muscle. This dual action is why Mounjaro tends to produce greater total weight loss than Ozempic at comparable doses.

But the GIP receptor’s presence in muscle raises an important question for muscle preservation research. GIP signalling in muscle may support protein synthesis – the process by which muscle fibres are built and maintained. If tirzepatide’s GIP activation has a muscle-protective effect, Mounjaro users might lose proportionally less lean mass than Ozempic users even as they lose more total weight.

What the Research Shows: Mounjaro vs Ozempic on Lean Mass

The SURMOUNT-1 trial for tirzepatide reported that approximately 28 to 33 percent of total weight loss was lean mass, depending on the dose. The STEP-1 trial for semaglutide reported similar figures of 30 to 37 percent lean mass as a proportion of total weight lost.

Head-to-head data is still limited, but a 2024 analysis published in Obesity Reviews pooled results from both drug programmes and found that tirzepatide users showed a modestly better lean mass preservation ratio compared to semaglutide users – approximately 3 to 5 percentage points better at equivalent weight loss levels. This is a small but clinically meaningful difference, particularly for patients who are already at risk of sarcopenia (age-related muscle loss).

Researchers theorise that tirzepatide’s GIP receptor activation in skeletal muscle tissue may be partially responsible for this advantage. GIP signalling promotes muscle glucose uptake and may stimulate anabolic (muscle-building) pathways that semaglutide, as a single agonist, cannot activate.

However, the absolute amount of muscle lost on Mounjaro is still significant. The drug’s superior weight loss efficacy means a patient might lose more total kilograms – and even if the lean mass percentage is better, the absolute kilograms of muscle lost may be comparable to or even greater than with Ozempic in patients achieving very large weight losses.

The Role of Protein and Resistance Exercise

Both drugs suppress appetite dramatically. This is a problem for muscle preservation because adequate protein intake is essential for maintaining lean mass during caloric restriction. Many patients on GLP-1 drugs find it difficult to eat more than 800 to 1,200 calories per day, and within that limited intake, protein often falls well below the recommended threshold.

Obesity medicine guidelines now consistently recommend that patients on GLP-1 therapy aim for at least 1.2 to 1.6 grams of protein per kilogram of target body weight per day. For a 90 kg individual targeting 75 kg, that means 90 to 120 grams of protein daily – a target that many patients on appetite-suppressing drugs struggle to reach.

Resistance exercise is the other critical factor. Multiple studies confirm that patients who combine GLP-1 therapy with structured resistance training preserve significantly more lean muscle mass than those who rely on drug therapy alone. Even two to three sessions per week of moderate resistance exercise – bodyweight exercises, resistance bands, or weights – can substantially reduce lean mass loss during rapid weight reduction.

Neither Ozempic nor Mounjaro comes with a compulsory exercise prescription, yet the research is clear: the drug alone is an incomplete treatment. Lifestyle integration is essential, and this matters more than which drug you choose.

GLP-1 Drugs and the Next Generation of Obesity Treatment

The pharmaceutical landscape is evolving rapidly. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, has shown even greater weight loss in Phase 2 trials – up to 24 percent body weight reduction at the highest dose. Researchers are also studying whether glucagon receptor co-activation, which stimulates fat breakdown and energy expenditure more aggressively, produces a more favourable muscle-to-fat loss ratio than current dual agonists.

Amycretin, a combination of amylin and GLP-1 receptor agonism, is another molecule in development that may better preserve lean mass due to amylin’s distinct effects on energy partitioning. The choice you make today may not be the best option available in 12 to 18 months. Staying informed about emerging data is an important part of long-term obesity management.

What Indian Patients Need to Know About GLP-1 Access

In India, both Ozempic (semaglutide) and Mounjaro (tirzepatide) are available but at significant cost. Monthly costs range from ?10,000 to ?25,000 depending on the dose and whether the drug is procured through a hospital or retail pharmacy. Coverage under standard health insurance for obesity indications remains limited, though coverage for type 2 diabetes is more widely available.

Indian patients with type 2 diabetes who are also overweight may be able to access semaglutide at a lower cost through diabetes management programmes. Patients considering GLP-1 therapy purely for weight management should discuss the full cost trajectory with their physician, as treatment typically continues indefinitely – weight is largely regained within 12 months of stopping.

For those seeking the metabolic benefits of GLP-1 activation without the cost and prescription requirement, our detailed guide on natural GLP-1 boosters available in India covers evidence-based dietary and supplement approaches that activate similar pathways.

If a pill form of semaglutide would make this treatment more accessible for you, read our full article on Ozempic now available as an oral pill – this option may be more practical and affordable than the injections for many patients.

Monitoring Your Body Composition During GLP-1 Treatment

Standard weight loss measurement – stepping on a scale – tells you nothing about the composition of what you are losing. A 10 kg loss could be 8 kg of fat and 2 kg of muscle, or 5 kg of each. The difference has enormous long-term consequences, yet most patients and their doctors are not tracking it.

If you are on a GLP-1 drug, consider requesting a DEXA scan (dual-energy X-ray absorptiometry) or bioelectrical impedance body composition analysis every 3 to 6 months. These tests reveal fat mass, lean mass, and bone density separately. Many private labs in Indian metros offer DEXA scans for ?2,000 to ?5,000. Tracking this data lets you and your doctor intervene early – increasing protein, adding resistance training, or reconsidering the drug choice – before significant muscle is lost.

For a comprehensive look at all the latest GLP-1 research including the surprising non-weight benefits, read our full article: Ozempic and Wegovy beyond weight loss – the 2026 research.

For related information on how body composition affects metabolic health long-term, see our research roundup on eccentric exercise for building muscle efficiently and creatine supplementation for lean mass and brain health.

Frequently Asked Questions